FGF23-parathyroid interaction: implications in chronic kidney disease (Q37654689)

21 August 2017

1 reference

title

FGF23-parathyroid interaction: implications in chronic kidney disease (English)

1 reference

21 August 2017

Hirotaka Komaba

1

1 reference

21 August 2017

Masafumi Fukagawa

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

9 December 2009

1 reference

21 August 2017

1 reference

21 August 2017

77

1 reference

21 August 2017

292-298

1 reference

21 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2009.466

21 August 2017

0 references

cites work

Dynamics of parathyroid hormone secretion in health and secondary hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Vitamin D receptor: mechanisms for vitamin D resistance in renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Phosphate and the parathyroid

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Endocrine functions of bone in mineral metabolism regulation.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Pathogenic role of Fgf23 in Hyp mice.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Regulation of fibroblast growth factor-23 signaling by klotho

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Klotho converts canonical FGF receptor into a specific receptor for FGF23

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Mutation of the mouse klotho gene leads to a syndrome resembling ageing

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Klotho ablation converts the biochemical and skeletal alterations in FGF23 (R176Q) transgenic mice to a Klotho-deficient phenotype

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

FGFR3 and FGFR4 do not mediate renal effects of FGF23.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Indirect regulation of PTH by estrogens may require FGF23.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Pathogenesis of secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

With or without the kidney: the role of FGF23 in CKD

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Post-transplant hypophosphatemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

1,25-dihydroxyvitamin D synthesis after renal transplantation: the role of fibroblast growth factor 23 and cyclosporine.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

As nature did not predict dialysis--what we can learn from FGF23 in end-stage renal disease?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.466

7 January 2021

Identifiers

DOI

10.1038/KI.2009.466

1 reference

Dimensions Publication ID

21 August 2017

0 references

1 reference